Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand

Pimwara Tanvejsilp (), Mark Loeb, Jonathan Dushoff and Feng Xie
Additional contact information
Pimwara Tanvejsilp: McMaster University
Mark Loeb: McMaster University
Jonathan Dushoff: McMaster University
Feng Xie: McMaster University

PharmacoEconomics - Open, 2018, vol. 2, issue 3, No 8, 297-308

Abstract: Abstract Background In Thailand, pharmaceutical care has been recently introduced to a tertiary hospital as an approach to improve adherence to tuberculosis (TB) treatment in addition to home visit and modified directly observed therapy (DOT). However, the economic impact of pharmaceutical care is not known. Objective The aim of this study was to estimate healthcare resource uses and costs associated with pharmaceutical care compared with home visit and modified DOT in pulmonary TB patients in Thailand from a healthcare sector perspective inclusive of out-of-pocket expenditures. Methods We conducted a retrospective study using data abstracted from the hospital billing database associated with pulmonary TB patients who began treatment between 2010 and 2013 in three hospitals in Thailand. We used generalized linear models to compare the costs by accounting for baseline characteristics. All costs were converted to international dollars (Intl$) Results The mean direct healthcare costs to the public payer were $519.96 (95%confidence interval [CI] 437.31–625.58) associated with pharmaceutical care, $1020.39 (95% CI 911.13–1154.11) for home visit, and $887.79 (95% CI 824.28–955.91) for modified DOT. The mean costs to patients were $175.45 (95% CI 130.26–230.48) for those receiving pharmaceutical care, $53.77 (95% CI 33.25–79.44) for home visit, and $49.33 (95% CI 34.03–69.30) for modified DOT. After adjustment for baseline characteristics, pharmaceutical care was associated with lower total direct costs compared with home visit (−$354.95; 95% CI −285.67 to −424.23) and modified DOT (−$264.61; 95% CI −198.76 to −330.46). Conclusion After adjustment for baseline characteristics, pharmaceutical care was associated with lower direct costs compared with home visit and modified DOT.

Date: 2018
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0053-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:3:d:10.1007_s41669-017-0053-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-017-0053-0

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().